Devergne O, Hatzivassiliou E, Izumi K M, Kaye K M, Kleijnen M F, Kieff E, Mosialos G
Department of Microbiology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Mol Cell Biol. 1996 Dec;16(12):7098-108. doi: 10.1128/MCB.16.12.7098.
The Epstein-Barr virus (EBV) transforming protein LMP1 appears to be a constitutively activated tumor necrosis factor receptor (TNFR) on the basis of an intrinsic ability to aggregate in the plasma membrane and an association of its cytoplasmic carboxyl terminus (CT) with TNFR-associated factors (TRAFs). We now show that in EBV-transformed B lymphocytes most of TRAF1 or TRAF3 and 5% of TRAF2 are associated with LMP1 and that most of LMP1 is associated with TRAF1 or TRAF3. TRAF1, TRAF2, and TRAF3 bind to a single site in the LMP1 CT corresponding to amino acids (aa) 199 to 214, within a domain which is important for B-lymphocyte growth transformation (aa 187 to 231). Further deletional and alanine mutagenesis analyses and comparison with TRAF binding sequences in CD40, in CD30, and in the LMP1 of other lymphycryptoviruses provide the first evidence that PXQXT/S is a core TRAF binding motif. The negative effects of point mutations in the LMP1(1-231) core TRAF binding motif on TRAF binding and NF-kappaB activation genetically link the TRAFs to LMP1(1-231)-mediated NF-kappaB activation. NF-kappaB activation by LMP1(1-231) is likely to be mediated by TRAF1/TRAF2 heteroaggregates since TRAF1 is unique among the TRAFs in coactivating NF-kappaB with LMP1(1-231), a TRAF2 dominant-negative mutant can block LMP1(1-231)-mediated NF-kappaB activation as well as TRAF1 coactivation, and 30% of TRAF2 is associated with TRAF1 in EBV-transformed B cells. TRAF3 is a negative modulator of LMP1(1-231)-mediated NF-kappaB activation. Surprisingly, TRAF1, -2, or -3 does not interact with the terminal LMP1 CT aa 333 to 386 which can independently mediate NF-kappaB activation. The constitutive association of TRAFs with LMP1 through the aa 187 to 231 domain which is important in NF-kappaB activation and primary B-lymphocyte growth transformation implicates TRAF aggregation in LMP1 signaling.
基于其在质膜中聚集的内在能力及其细胞质羧基末端(CT)与肿瘤坏死因子受体相关因子(TRAF)的关联,爱泼斯坦-巴尔病毒(EBV)转化蛋白LMP1似乎是一种组成型激活的肿瘤坏死因子受体(TNFR)。我们现在表明,在EBV转化的B淋巴细胞中,大多数TRAF1或TRAF3以及5%的TRAF2与LMP1相关联,并且大多数LMP1与TRAF1或TRAF3相关联。TRAF1、TRAF2和TRAF3结合到LMP1 CT中对应于氨基酸(aa)199至214的单个位点,该位点位于对B淋巴细胞生长转化很重要的结构域(aa 187至231)内。进一步的缺失和丙氨酸诱变分析以及与CD40、CD30和其他淋巴细胞隐病毒的LMP1中TRAF结合序列的比较提供了首个证据,即PXQXT/S是核心TRAF结合基序。LMP1(1 - 231)核心TRAF结合基序中的点突变对TRAF结合和NF-κB激活的负面影响从基因上把TRAF与LMP1(1 - 231)介导的NF-κB激活联系起来。LMP1(1 - 231)介导的NF-κB激活可能由TRAF1/TRAF2异源聚集体介导,因为TRAF1在与LMP1(1 - 231)共激活NF-κB方面在TRAF中是独特的,一个TRAF2显性负性突变体可以阻断LMP1(1 - 231)介导的NF-κB激活以及TRAF1共激活,并且在EBV转化的B细胞中30%的TRAF2与TRAF1相关联。TRAF3是LMP1(1 - 231)介导的NF-κB激活的负调节因子。令人惊讶的是,TRAF1、-2或-3不与可以独立介导NF-κB激活的LMP1 CT末端氨基酸333至386相互作用。TRAF通过对NF-κB激活和原代B淋巴细胞生长转化很重要的187至231氨基酸结构域与LMP1组成型关联,这表明TRAF聚集参与LMP1信号传导。